Aurinia Pharmaceuticals
Victoria, US · Founded 2009 · 3 known investors
Find your way into Aurinia Pharmaceuticals
Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
Founders & leadership
Aurinia Pharmaceuticals was founded in 2009 by Richard M. Glickman.
RM
Richard M. GlickmaninFounder · CEO2017–2023
SW
Stephen W. ZarubyExecutive
MM
Michael MartininFounder, Interim CEO, Chief Operating/Business Officer & Board Member2012–2024Michael Martin is CEO of Aurinia Pharmaceuticals, a biopharmaceutical company developing therapies for autoimmune diseases. With nearly three decades in the biotech and pharmaceutical sector, he has held executive roles in commercial business units, corporate strategy, and business development, and was involved in bringing multiple products to market including CellCept, Remicade, and LUPKYNIS.
DB
Dennis BourgeaultExecutive
MT
Mr. TangChief Executive Officer and Chair of the Board
Board
KV
BR
Benjamin RovinskiBoard director
CK
Chris KimBoard director
DW
Donald WyattBoard director
DP
Daniel ParkBoard director
PW
Peter WijngaardBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$52M disclosed across 1 round · 2014
▶$52MraisedFeb 2014 · 22 investors · BiotechnologyRule 506(b)
▶$52MraisedFeb 2014 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kurt von EmsterDirector
- Benjamin RovinskiDirector
- Chris KimDirector
- Donald WyattDirector
- Stephen W. ZarubyExecutive Officer, Director
- Michael MartinExecutive Officer, Director
- Dennis BourgeaultExecutive Officer
- Daniel ParkDirector
- Richard M. GlickmanExecutive Officer, Director
- Peter WijngaardDirector
- Offering amount
- $52M
- Amount sold
- $52M
- Sales commissions
- $3.5M
- Placement agents
- Canaccord Genuity Inc., Leerink Partners LLC
- First sale
- Feb 2014
- Incorporated
- Corporation, Alberta, Canada, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buybackfinance.yahoo.com · Aug 2026
Aurinia Pharmaceuticals (AUPH) deal pushes back Teva lupus drug genericstocktitan.net · Aug 2026
Will Aurinia’s Reaffirmed 2026 Guidance and Large Buyback Reshape Aurinia Pharmaceuticals' (AUPH) Narrative? - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Aurinia Pharmaceuticals do?
- Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
- Who founded Aurinia Pharmaceuticals?
- Aurinia Pharmaceuticals was founded by Richard M. Glickman in 2009.
- Who are Aurinia Pharmaceuticals's investors?
- Aurinia Pharmaceuticals's investors include Lumira Ventures, New Enterprise Associates (NEA), venBio Partners.
- How much funding has Aurinia Pharmaceuticals raised?
- Aurinia Pharmaceuticals has disclosed $52M raised across 1 round.
- Where is Aurinia Pharmaceuticals headquartered?
- Aurinia Pharmaceuticals is headquartered in Victoria, US.